Top

Published in:

01-11-2014 | Original Research Article

Impact of the Pharmacist Medication Review Services on Drug-Related Problems and Potentially Inappropriate Prescribing of Renally Cleared Medications in Residents of Aged Care Facilities

Authors: Pankti A. Gheewala, Gregory M. Peterson, Colin M. Curtain, Prasad S. Nishtala, Paul J. Hannan, Ronald L. Castelino

Published in: Drugs & Aging | Issue 11/2014

Abstract

Background

Drug-related problems (DRPs) are common in aged care facilities and few studies have been conducted to determine the impact of the pharmacist-conducted medication review services. Studies determining the prevalence of chronic kidney disease (CKD) and data regarding inappropriate prescribing of renally cleared medications in aged care facilities in Australia are also lacking.

Objectives

To investigate the number and nature of DRPs identified and recommendations made by pharmacists in residents of aged care facilities. To determine the prevalence of CKD and estimate the magnitude of inappropriate prescribing of renally cleared medications in residents of aged care facilities.

Methods

DRPs identified and recommendations made by pharmacists were classified using the adapted version of the DOCUMENT classification system. The modification of diet in renal disease formula was used to estimate the prevalence of CKD, and the Cockcroft–Gault formula was used to estimate the magnitude of inappropriate prescribing of renally cleared medications.

Results

Over 98 % of residents of aged care facilities had at least one DRP. Most (83.8 %) recommendations made by accredited pharmacists to resolve DRPs were accepted by general practitioners. CKD was prevalent in 48 % of residents, and inappropriate prescribing of renally cleared medications was identified in 28 (16 %) residents with CKD.

Conclusions

DRPs are common in aged care facilities and the impact of medication review services appears to be high. CKD is also common among residents of aged care facilities, and inappropriate prescribing of renally cleared medications was also prevalent, warranting attention to regular renal function monitoring and appropriate drug and dose selection in residents of aged care facilities.

Available only for authorised users

Hamilton HJ, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr. 2009;9:5. doi:10.1186/1471-2318-9-5.PubMedCrossRefPubMedCentral

Williams M, Peterson GM, Tenni PC, et al. DOCUMENT: a system for classifying drug-related problems in community pharmacy. Int J Clin Pharm. 2012;34(1):43–52. doi:10.1007/s11096-011-9583-1.PubMedCrossRef

Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24. doi:10.1001/archinte.163.22.2716.PubMedCrossRef

Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002;18(3):577–92.PubMedCrossRef

Walley T, Scott AK. Prescribing in the elderly. Postgrad Med J. 1995;71(838):466–71.PubMedCrossRefPubMedCentral

Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.PubMedCrossRefPubMedCentral

ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14(5):488–98. doi:10.1097/01.mjt.0000183719.84390.4d.PubMedCrossRef

Stafford AC, Alswayan MS, Tenni PC. Inappropriate prescribing in older residents of Australian care homes. J Clin Pharm Ther. 2011;36(1):33–44. doi:10.1111/j.1365-2710.2009.01151.x.PubMedCrossRef

Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother. 2009;43(6):1096–106. doi:10.1345/aph.1L700.PubMedCrossRef

10.

Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med. 1992;117(8):684–9.PubMedCrossRef

11.

Gill SS, Misiaszek BC, Brymer C. Improving prescribing in the elderly: a study in the long term care setting. Can J Clin Pharmacol. 2001;8(2):78–83.PubMed

12.

O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437–52. doi:10.2165/11632610-000000000-00000.PubMedCrossRef

13.

Ruggiero C, Dell’Aquila G, Gasperini B, et al. Potentially inappropriate drug prescriptions and risk of hospitalization among older, Italian, nursing home residents: the ULISSE project. Drugs Aging. 2010;27(9):747–58. doi:10.2165/11538240-000000000-00000.PubMedCrossRef

14.

Hanlon JT, Wang X, Handler SM, et al. Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients. J Am Med Dir Assoc. 2011;12(5):377–83. doi:10.1016/j.jamda.2010.04.008.PubMedCrossRefPubMedCentral

15.

Rahimi AR, Kennedy K, Thomason M, et al. Improper renal dosing in long-term care facilities. South Med J. 2008;101(8):802–5. doi:10.1097/SMJ.0b013e31817f1f71.PubMedCrossRef

16.

Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.PubMedCrossRef

17.

Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83. doi:10.1056/NEJMra054415.PubMedCrossRef

18.

Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney disease. Blood Purif. 2011;31(1–3):138–45. doi:10.1159/000321857.PubMedCrossRef

19.

Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47. doi:10.1001/jama.298.17.2038.PubMedCrossRef

20.

Jose MD, Otahal P, Kirkland G, et al. Chronic kidney disease in Tasmania. Nephrology (Carlton). 2009;14(8):743–9. doi:10.1111/j.1440-1797.2009.01198.x.PubMedCrossRef

21.

Rothberg MB, Kehoe ED, Courtemanche AL, et al. Recognition and management of chronic kidney disease in an elderly ambulatory population. J Gen Intern Med. 2008;23(8):1125–30. doi:10.1007/s11606-008-0607-z.PubMedCrossRefPubMedCentral

22.

Papaioannou A, Clarke JA, Campbell G, et al. Assessment of adherence to renal dosing guidelines in long-term care facilities. J Am Geriatr Soc. 2000;48(11):1470–3.PubMed

23.

Department of Health. Medication Management Reviews/Residential Medication Management Review. 2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/medication_management_reviews.htm. Accessed 30 Sep 2013.

24.

Nishtala PS, Hilmer SN, McLachlan AJ, et al. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86. doi:10.2165/11316440-000000000-00000.PubMedCrossRef

25.

Pharmaceutical Society of Australia. Guidelines for pharmacists providing Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM). 2011. http://www.psa.org.au/aprc-residential-medication-review/unserstand-service-information. Accessed 30 Sep 2013.

26.

Nishtala PS, McLachlan AJ, Bell JS, et al. A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. J Eval Clin Pract. 2011;17(1):97–103. doi:10.1111/j.1365-2753.2010.01374.x.PubMedCrossRef

27.

Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol. 2001;51(3):257–65.PubMedCrossRefPubMedCentral

28.

Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes: randomised controlled trial. Age Ageing. 2006;35(6):586–91. doi:10.1093/ageing/afl075.PubMedCrossRef

29.

WHO Collaborating Centre for Drug Statistics Mthodology. Anatomical Therapeutic Chemical (ATC) Classification System. Norweigan Institute of Public Health. http://www.whocc.no/atc_ddd_publications/atc_ddd_index/. Accessed 25 Sep 2013.

30.

WHO. International Classification of Diseases (ICD)-10, version 2010. http://www.who.int/classifications/icd/en/. Accessed 25 Sep 2013.

31.

Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 2009;54(1):33–42. doi:10.1053/j.ajkd.2009.03.008.PubMedCrossRefPubMedCentral

32.

Australian Medicines Handbook (AMH). Evidence-based independent medicines reference. 2014. https://shop.amh.net.au/. Accessed 21 July2014.

33.

Faull R, Lee L. Prescribing in renal disease. Australian Prescriber. 2007. http://www.australianprescriber.com/magazine/30/1/17/20. Accessed 25 Sep 2013.

34.

R Core Team (2013) R: A language for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.r-project.org/. Accessed 3 Oct 2013.

35.

Finkers F, Maring JG, Boersma F, et al. A study of medication reviews to identify drug-related problems of polypharmacy patients in the Dutch nursing home setting. J Clin Pharm Ther. 2007;32(5):469–76. doi:10.1111/j.1365-2710.2007.00849.x.PubMedCrossRef

36.

Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87–94.PubMedCrossRef

37.

Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41. doi:10.1016/j.amjopharm.2006.03.002.PubMedCrossRef

38.

Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251–8. doi:10.1016/j.amjmed.2004.09.018.PubMedCrossRef

39.

Vlasses PH, Lucarotti RL, Miller DA, et al. Drug therapy review in a skilled nursing facility: an innovative approach. J Am Pharm Assoc. 1977;17(2):92–4.PubMed

40.

Mandryk JA, Wai A, Mackson JM, et al. Evaluating the impact of educational interventions on use of antithrombotics in Australia. Pharmacoepidemiol Drug Saf. 2008;17(2):160–71. doi:10.1002/pds.1536.PubMedCrossRef

41.

Schoen C, Osborn R, Huynh PT, et al. Taking the pulse of health care systems: experiences of patients with health problems in six countries. Health Aff (Millwood). 2005;Suppl Web Exclusives:W5-509-25. doi:10.1377/hlthaff.w5.509.

42.

Harding G, Wilcock M. Community pharmacists’ perceptions of medicines use reviews and quality assurance by peer review. Pharm World Sci. 2010;32(3):381–5. doi:10.1007/s11096-010-9381-1.PubMedCrossRef

43.

McClellan WM, Resnick B, Lei L, et al. Prevalence and severity of chronic kidney disease and anemia in the nursing home population. J Am Med Dir Assoc. 2010;11(1):33–41. doi:10.1016/j.jamda.2009.07.003.PubMedCrossRef

44.

Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014;44(1):77–85. doi:10.1111/imj.12291.PubMedCrossRef

45.

Sweileh WM, Janem SA, Sawalha AF, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16(8):908–12. doi:10.1002/pds.1412.PubMedCrossRef

46.

Decloedt E, Leisegang R, Blockman M, et al. Dosage adjustment in medical patients with renal impairment at Groote Schuur Hospital. S Afr Med J. 2010;100(5):304–6.PubMed

47.

Khanal A, Peterson GM, Castelino RL, et al. Renal drug dosing recommendations: evaluation of product information for brands of the same drug. Intern Med J. 2014;44(6):591–6. doi:10.1111/imj.12446.PubMedCrossRef

48.

Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57(2):335–40. doi:10.1111/j.1532-5415.2008.02098.x.PubMedCrossRefPubMedCentral

49.

Desrochers JF, Lemieux JP, Morin-Belanger C, et al. Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. Am J Kidney Dis. 2011;58(4):527–35. doi:10.1053/j.ajkd.2011.04.020.PubMedCrossRef

Title: Impact of the Pharmacist Medication Review Services on Drug-Related Problems and Potentially Inappropriate Prescribing of Renally Cleared Medications in Residents of Aged Care Facilities
Authors: Pankti A. Gheewala
Gregory M. Peterson
Colin M. Curtain
Prasad S. Nishtala
Paul J. Hannan
Ronald L. Castelino
Publication date: 01-11-2014
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 11/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-014-0208-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2014

Considerations in the Treatment of Tension-Type Headache in the Elderly

Cutaneous Adverse Drug Reactions in the Elderly: a Retrospective Analysis in Thailand

Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK

Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout

Safety Considerations of Inhaled Corticosteroids in the Elderly

Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials